StreetInsider.com News Articles

argenx SE (ARGX) PT Raised to $1,291 at Wells Fargo

Mon, 01 Jun 2026 06:54:56 -0400

Wells Fargo analyst Derek Archila raised the price target on argenx SE (NASDAQ: ARGX) to $1,291.00 (from $1,260.00) while maintaining a Overweight rating.

argenx SE (ARGX) PT Raised to $1,255 at Stifel

Thu, 28 May 2026 16:07:23 -0400

Stifel analyst Alex Thompson raised the price target on argenx SE (NASDAQ: ARGX) to $1,255.00 (from $1,222.00) while maintaining a Buy rating.

The analyst comments "3Q26 Ph3 data for the ALKIVIA study of efgartigimod in Myositis is the most important catalyst for ARGX in 2026, in our view. While growth in MG and CIDP remains steady, competition is growing. We see success in Myositis as vital for continued topline efgartigimod growth over the medium term. The key debate is focused less on the likelihood of efgartigimod to hit the primary endpoint in the overall population (high) but rather what is the

argenx SE (ARGX) PT Raised to $1,255 at Stifel

Thu, 28 May 2026 16:07:23 -0400

Stifel analyst Alex Thompson raised the price target on argenx SE (NASDAQ: ARGX) to $1,255.00 (from $1,222.00) while maintaining a Buy rating.

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

May 28, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on Tuesday, June 23, 2026, at 2:00pm ET.

The second webinar in the Company’s ‘mini’ series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

argenx to Host Myositis R&D Webinar on June 23, 2026

Thu, 28 May 2026 01:00:00 -0400

argenx to Present at Upcoming Investor Conferences

Wed, 27 May 2026 01:00:00 -0400

May 27, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June:

William Blair 46th Annual Growth Stock Conference. Presentation on Wednesday, June 3, 2026 at 12:40 p.m. CT in Chicago, IL.
Goldman Sachs 47th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 9, 2026 at 4:00 p.m. ET in Miami, FL.